Cytosorbents (CTSO) Cash & Equivalents (2010 - 2026)

Cytosorbents has reported Cash & Equivalents for 17 years, with the latest figure at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 63.39% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 63.39% YoY), and the FY2025 full-year result was $6.2 million, down 36.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.8 million, down from $6.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $43.0 million in Q1 2022, with the low at $4.8 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $14.5 million across 5 years, with a median of $10.2 million in 2025.
• Annual changes were most pronounced in 2025 — Cash & Equivalents surged 56.98% — and 2026, when it tumbled 63.39%.
• Cytosorbents' Cash & Equivalents stood at $22.1 million in 2022, then slumped by 36.19% to $14.1 million in 2023, then sank by 30.9% to $9.8 million in 2024, then slumped by 36.0% to $6.2 million in 2025, then retreated by 23.19% to $4.8 million in 2026.
• The last three Cash & Equivalents figures came in at $4.8 million (Q1 2026), $6.2 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.